CC BY NCPeter NashAndreas KerschbaumerRoy M FleischmannJanet E PopeMichaela Stoffer-MarxTsutomu TakeuchiMichael TraunerXenofon BaraliakosWolf-Henning BoehnckeJohn D IsaacsWalter P MaksymowychLai-Shan TamRicardo XavierThomas DörnerMaxime DougadosKlaus GeisslerIain McInnesDésirée van der HeijdeKevin L WinthropMaarten de WitDaniel AletahaPaul EmeryJoel KremerEun Bong LeeMarieke VoshaarYoshiya TanakaFilip van den BoschRené WesthovensJosef S Smolen2025-06-162025-06-162021-01-010003-496710.1136/annrheumdis-2020-218398https://trapdev.rcub.bg.ac.rs/handle/123456789/631789Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.Existing data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration.The Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale.The consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.OPENRheumatoid/drug therapy/immunologyINTERLEUKIN-6Piperidines/therapeutic useRESPONSEPyridinesClinical sciencesAntirheumatic Agents/therapeutic useAdamantanePsoriasis/drug therapy/immunologyTHERAPYArthritis, RheumatoidDOUBLE-BLINDPsoriatic/drug therapy/immunologyPyrazoles/therapeutic usePiperidinesHeterocyclic Compoundsinfo:eu-repo/classification/ddc/616Medicine and Health SciencesPurines/therapeutic useRECEPTOR INHIBITIONPyridines/therapeutic useddc:616Public healthAdamantane/analogs & derivatives/therapeutic useInflammatory Bowel Diseases/drug therapy/immunologyEuropeEULAR RECOMMENDATIONSAntirheumatic AgentsCombination3-Ring/therapeutic useNiacinamide/analogs & derivatives/therapeutic useCytokinesSpondylarthropathies/drug therapy/immunologyDrug Therapy, CombinationAnkylosing/drug therapy/immunologyTriazoles/therapeutic useHeterocyclic Compounds, 3-RingNiacinamideImmunologyAdvisory CommitteesTherapeuticsINADEQUATEAzetidines/therapeutic useAutoimmune DiseasesHERPES-ZOSTERCytokines/immunologyDrug TherapyRheumatologyHealth services and systemsHumansJanus Kinase InhibitorsPsoriasisACTIVE PSORIATIC-ARTHRITISInflammationVENOUS THROMBOEMBOLISMArthritisJanus Kinase Inhibitors/therapeutic useArthritis, PsoriaticPyrimidines/therapeutic useSulfonamides/therapeutic useRecommendationInflammatory Bowel DiseasesRHEUMATOID-ARTHRITISMAINTENANCEPyrimidinesPurinesMODIFYING ANTIRHEUMATIC DRUGSAzetidinesPyrazolesSpondylitispublication0302 clinical medicine03 medical and health sciences3. Good healthdoi_dedup___PMC7788060331588811854/LU-869769410072/399663